TAIAN CITY, China, May 29 /Xinhua-PRNewswire-FirstCall/ -- China Biologic Products, Inc. (OTC Bulletin Board: CBPO) ("CBP," or the "Company"), one of the leading plasma-based pharmaceutical companies in the People's Republic of China ("China" or the "PRC"), today announced that the Company has been approved by the Chinese State Food and Drug Administration (the "SFDA") to commence the production of Human Albumin 12.5g/vial (25%, 50 ml).
Human Albumin 12.5g/vial (25%, 50 ml), contains the highest concentration and delivers the highest dosage of the Human Albumin family products in Mainland China, and has a better effect on the clinical application for ascites due to liver cirrhosis, external injuries, hydrocephalus due to cerebral hemorrhage, serious hypoproteinemia, and other major diseases. With this approval, CBP is now one of the few producers offering the widest range of Human Albumin products available in China.
"We are pleased to receive approval from the SFDA to produce this concentration and dosage of Human Albumin," said Mr. Chaoming Zhao, CFO of China Biologic. "The approval represents a significant milestone for our Company."
The Company has already commenced the production and marketing of this new product.
About China Biologic Products, Inc.
Through its indirect majority-owned subsidiary Shandong Taibang Biological Products Co. Ltd., China Biologic Products, Inc. (the "Company"), is principally engaged in the research, development, production and manufacturing and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China. The Company's human albumin products are mainly used to increase blood volume and its immunoglobulin products are used for the treatment and prevention diseases.
Safe Harbor Statement
This release may contain certain "forward-looking statements" relating
to the business of China Biologic Products, Inc. and its subsidiary
companies. All statements, other than statements of historical fact
included herein are "forward-looking statements," including statements
regarding: the significance of the new Human Albumin product to the
Company, the ability of the Company to achieve its commercial objectives;
the business strategy, plans and objectives of the Company and its
subsidiaries; and any other statements of non- historical information.
These forward-looking statements are often identified by the use of
forward-looking terminology such as "believes," "expects" or similar
expressions, involve known and unknown risks and uncertainties. Although
the Company believes that the expectations reflected in these
forward-looking statements are reasonable, they do involve assumptions,
risks and uncertainties, and these expectations may prove to be incorrect.
Investors should not place undue reliance on these forward-looking
statements, which speak only as of the date of this press release. The
Company's actual results could differ materially from those anticipated in
these forward-looking statements as a result of a variety of factors,
including those discussed in the Company's periodic reports that are filed
with the Securities and Exchange Commission and available on its website
(http://www.sec.gov). All forward- looking statements attributable to the
Company or persons acting on its behalf are expressly qualified in their
entirety by these factors. Other than as required under the securities
laws, the Company does not assume a duty to update these forward-looking
For more information, please contact:
Mr. Y. Tristan Kuo
Vice President, Finance
China Biologic Products, Inc.
Investor Relations Contact:
Mr. Crocker Coulson
CCG Elite Investor Relations
Tel: +1-646-213-1915 (NY office)
|SOURCE China Biologic Products, Inc.|
Copyright©2008 PR Newswire.
All rights reserved